Severe Asthma
Conditions
Interventions
Niet van toepassing
Sponsors
Amsterdam UMC, University of Amsterdam
Eligibility
Inclusion criteria
Inclusion criteria: - Adult patients with severe refractory eosinophilic asthma who are treated with Mepolizumab. -Poor asthma control or frequent (≥2 per year) exacerbations, despite high-intensity treatment while alternative diagnoses have been excluded, comorbidities are treated and compliance has been checked. -Peripheral blood eosinophil levels ≥150 cells/µl.
Exclusion criteria
Exclusion criteria: - Alcohol use <12 hours prior to measurement. - Unwillingness or inability to comply with the study protocol for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - eNose ‘Breathprints’ (signature of mixtures of volatile organic compounds (VOCs) in exhaled breath) | — |
Secondary
| Measure | Time frame |
|---|---|
| -Absence of exacerbations during 12 months after initiation of mepolizumab therapy. -Improvement of Asthma Control Questionnaire (ACQ)-score by 0.5 points over 6 months. -Decrease of oral corticosteroid (OCS) use by 50% after 12 months. -Any switch of biological therapy. | — |
Contacts
Public ContactA.H. Maitland-van der Zee
-
Outcome results
None listed